Clinical Research Directory

Inclusion Criteria: * age between 18 and 85 years; * first stroke with neurological outcomes affecting the upper limb; * patients with severe or moderate hemiparesis (FM-UL≤44), stratified according to severe (FM-UL ≤ 22) or moderate (22 \<FM-UL ≤ 44) motor deficit; * patients in the sub-acute phase within 90 days of the acute event, stratified by the distance from the acute event (OAI≤30; OAI\> 30); * Modified Ashworth Scale (MAS) of the main components (shoulder, elbow, and wrist) of the upper limb \<3; * sufficient cognitive and linguistic level to understand the instructions and provide consent; * signed informed consent. Exclusion Criteria: * unstable general clinical conditions; * severe visual impairment; * inability to maintain the sitting position; * mild motor deficit of the arm (FM-UL\> 44) at baseline; * recent botox injection in the upper limb or planned botox injection during the study period, including the follow-up; * inability to don the orthosis on the impaired upper limb; * bone instability in relevant areas of the upper extremity (unconsolidated fractures, fractures due to osteoporosis); * fixed contractures involving the impaired upper limb (e.g. frozen shoulder); * shoulder instability; * severe pain syndromes caused or intensified by rehabilitation with Armeo Power; * patients who need isolation for infectious diseases ; * epileptic disorder with frequent attacks that carry the risk of having a seizure during rehabilitation with Armeo Power; * history of physical or neurological conditions that interfere with study procedures or assessment of motor function; * interruption of treatment for 1 week, or 5 consecutive sessions; * participation in other innovative treatment protocols for the upper limb rehabilitation (e.g. robotics, virtual reality, AOT ... etc).